TCG Crossover Management, LLC
- SEC CIK
- 0001839948
Holdings, Q2 2026
Positions as of Jun 30, 2026, filed Aug 14, 2026.SEC
- Positions
- 54
- +5 vs. Q1 2026
- Total value
- $4.16B
- +$665.14M (+19.0%) vs. Q1 2026
Compare with Q1 2026: new, added, reduced and sold out
Positions
Long positions only. Changes compare share counts with Q1 2026.
| Security | Class | Shares | Value | % of portfolio | Change in shares | Action | History |
|---|---|---|---|---|---|---|---|
| ABVXABIVAX SA | SPONSORED ADS | 6,007,834 | $800.6M | 19.24% | −473,251−7.3% | Reduced | View |
| TNGXTANGO THERAPEUTICS INC | COM | 9,081,201 | $283.88M | 6.82% | −1,449,870−13.8% | Reduced | View |
| CGONCG ONCOLOGY INC | COM | 3,670,206 | $260.77M | 6.27% | 00.0% | Unchanged | View |
| COGTCOGENT BIOSCIENCES INC | COM | 4,854,436 | $187.87M | 4.52% | −92,458−1.9% | Reduced | View |
| IMVTIMMUNOVANT INC | COM | 4,457,988 | $171.77M | 4.13% | 00.0% | Unchanged | View |
| SYRESPYRE THERAPEUTICS INC | COM NEW | 1,900,582 | $168.73M | 4.06% | 00.0% | Unchanged | View |
| DNTHDIANTHUS THERAPEUTICS INC | COM | 1,676,624 | $163.44M | 3.93% | 00.0% | Unchanged | View |
| MIRMMIRUM PHARMACEUTICALS INC | COM | 1,062,049 | $124.33M | 2.99% | 00.0% | Unchanged | View |
| ZLABZAI LAB LTD | ADR | 6,137,627 | $116.61M | 2.80% | +6,137,627 | New | View |
| AMLXAMYLYX PHARMACEUTICALS INC | COM | 6,243,812 | $112.14M | 2.70% | 00.0% | Unchanged | View |
| GLUEMONTE ROSA THERAPEUTICS INC | COM | 4,622,151 | $111.86M | 2.69% | 00.0% | Unchanged | View |
| BCRXBIOCRYST PHARMACEUTICALS INC | COM | 11,020,968 | $110.21M | 2.65% | 00.0% | Unchanged | View |
| VORVOR BIOPHARMA INC | COM NEW | 5,673,078 | $104.44M | 2.51% | 00.0% | Unchanged | View |
| TYRATYRA BIOSCIENCES INC | COM | 3,248,980 | $103.77M | 2.49% | 00.0% | Unchanged | View |
| DYNDYNE THERAPEUTICS INC | COM | 4,615,144 | $102.5M | 2.46% | 00.0% | Unchanged | View |
| IRONDISC MEDICINE INC | COM | 1,341,862 | $98.14M | 2.36% | 00.0% | Unchanged | View |
| RLAYRELAY THERAPEUTICS INC | COM | 4,273,356 | $79.95M | 1.92% | 00.0% | Unchanged | View |
| SVRASAVARA INC | COM | 12,362,205 | $76.15M | 1.83% | 00.0% | Unchanged | View |
| AURAAURA BIOSCIENCES INC | COM | 9,533,333 | $67.69M | 1.63% | +9,533,333 | New | View |
| RVMDREVOLUTION MEDICINES INC | COM | 340,899 | $63.84M | 1.53% | −235,574−40.9% | Reduced | View |
| TRAXFIRST TRACKS BIOTHERAPEUTICS | ORD SHS | 2,895,304 | $58.25M | 1.40% | +2,895,304 | New | View |
| KODKODIAK SCIENCES INC | COM | 1,445,538 | $56.32M | 1.35% | 00.0% | Unchanged | View |
| AVTXAVALO THERAPEUTICS INC | COM NEW | 3,017,120 | $55.76M | 1.34% | +2,278,737+308.6% | Added | View |
| LBRXLB PHARMACEUTICALS INC | COM SHS | 1,447,310 | $46.97M | 1.13% | −392,179−21.3% | Reduced | View |
| IPSCCENTURY THERAPEUTICS INC | COM | 17,754,430 | $43.4M | 1.04% | 00.0% | Unchanged | View |
| TECXTECTONIC THERAPEUTIC INC | COM | 1,204,891 | $41.42M | 1.00% | 00.0% | Unchanged | View |
| XNCRXENCOR INC | COM | 2,452,138 | $39.48M | 0.95% | 00.0% | Unchanged | View |
| SRZNSURROZEN INC | COM NEW | 1,473,101 | $38.23M | 0.92% | 00.0% | Unchanged | View |
| EDITEDITAS MEDICINE INC | COM | 11,111,111 | $36M | 0.87% | +11,111,111 | New | View |
| MBXMBX BIOSCIENCES INC | COM | 650,000 | $35.88M | 0.86% | 00.0% | Unchanged | View |
| PHVSPHARVARIS N V | COM | 1,008,229 | $34.86M | 0.84% | +1,008,229 | New | View |
| SLNSILENCE THERAPEUTICS PLC | ADS | 3,033,560 | $33.31M | 0.80% | 00.0% | Unchanged | View |
| IFRXINFLARX NV | COM | 14,500,000 | $32.48M | 0.78% | +14,500,000 | New | View |
| ALTALTIMMUNE INC | COM NEW | 10,000,000 | $30.4M | 0.73% | +10,000,000 | New | View |
| JANXJANUX THERAPEUTICS INC | COM | 1,789,617 | $27.49M | 0.66% | 00.0% | Unchanged | View |
| CATXPERSPECTIVE THERAPEUTICS INC | COM NEW | 7,915,567 | $26.99M | 0.65% | 00.0% | Unchanged | View |
| AGMBAGOMAB THERAPEUTICS NV | SPONSORED ADS | 2,053,233 | $26.65M | 0.64% | 00.0% | Unchanged | View |
| BHVNBIOHAVEN LTD | COM | 1,779,952 | $26.49M | 0.64% | −2,851,365−61.6% | Reduced | View |
| AKTSAKTIS ONCOLOGY INC | COM | 696,560 | $22.45M | 0.54% | +696,560 | New | View |
| ALECALECTOR INC | COM | 10,000,000 | $20.1M | 0.48% | 00.0% | Unchanged | View |
| FORTE BIOSCIENCES INC34962G208 | COM NEW | 920,000 | $19.55M | 0.47% | +920,000 | New | – |
| MNPRMONOPAR THERAPEUTICS INC | COM NEW | 203,327 | $18.83M | 0.45% | +71,224+53.9% | Added | View |
| OCULOCULAR THERAPEUTIX INC | COM | 1,647,752 | $16.18M | 0.39% | 00.0% | Unchanged | View |
| ADCTADC THERAPEUTICS SA | SHS | 11,390,175 | $12.19M | 0.29% | 00.0% | Unchanged | View |
| ALXOALX ONCOLOGY HLDGS INC | COM | 5,655,487 | $11.71M | 0.28% | −7,356,362−56.5% | Reduced | View |
| TRDAENTRADA THERAPEUTICS INC | COM | 1,060,230 | $7.8M | 0.19% | −1,227,270−53.7% | Reduced | View |
| CGEMCULLINAN THERAPEUTICS INC | COM | 406,786 | $7.41M | 0.18% | 00.0% | Unchanged | View |
| ARVNARVINAS INC | COM | 707,098 | $5.88M | 0.14% | −1,680,363−70.4% | Reduced | View |
| KRROKORRO BIO INC | COM | 416,301 | $5.49M | 0.13% | 00.0% | Unchanged | View |
| RACCRESEARCH ALLIANCE CORP III | ORD SHS CL A | 500,000 | $5.35M | 0.13% | +500,000 | New | View |
| LONALEONABIO INC | COM | 464,398 | $4.27M | 0.10% | 00.0% | Unchanged | View |
| JATTJATT II ACQUISITION CORP | ORD SHS | 200,000 | $2.27M | 0.05% | +200,000 | New | View |
| CNTXCONTEXT THERAPEUTICS INC | COM | 2,682,696 | $1.49M | 0.04% | 00.0% | Unchanged | View |
| EIKNEIKON THERAPEUTICS INC | COM | 37,902 | $494.62K | 0.01% | +37,902 | New | View |
Sold out since Q1 2026 (7)
Positions held at the end of Q1 2026 that are no longer in this filing.
| Security | Class | Shares, Q1 2026 | Value, Q1 2026 | % of portfolio, Q1 2026 |
|---|---|---|---|---|
| CENTESSA PHARMACEUTICALS PLC152309100 | SPONSORED ADS | 4,286,480 | $170.26M | 4.87% |
| FULCFULCRUM THERAPEUTICS INC | COM | 5,250,000 | $40.27M | 1.15% |
| LQDALIQUIDIA CORPORATION | COM NEW | 403,048 | $15.21M | 0.44% |
| URGNUROGEN PHARMA LTD | COM | 405,365 | $7.29M | 0.21% |
| GPCRSTRUCTURE THERAPEUTICS INC | SPONSORED ADS | 140,411 | $6.77M | 0.19% |
| UPBUPSTREAM BIO INC | COM | 181,063 | $1.63M | 0.05% |
| VTGNVISTAGEN THERAPEUTICS INC | COM | 2,676,580 | $1.53M | 0.04% |
13F filings by quarter
| Quarter | Filed | Positions | Total value | Changes | Filing |
|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 54 | $4.16B | vs. Q1 2026 | SEC |
| Q1 2026 | May 15, 2026 | 49 | $3.5B | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 17, 2026 | 43 | $3.02B | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 17, 2025 | 40 | $2.03B | vs. Q2 2025 | SEC |
| Q2 2025 | Aug 14, 2025 | 37 | $875.51M | vs. Q1 2025 | SEC |
| Q1 2025 | May 14, 2025 | 37 | $733.09M | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 14, 2025 | 38 | $1.02B | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 14, 2024 | 36 | $1.18B | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 14, 2024 | 32 | $959.5M | vs. Q1 2024 | SEC |
| Q1 2024 | May 15, 2024 | 33 | $1.26B | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 14, 2024 | 29 | $901.7M | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 14, 2023 | 26 | $679.11M | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 14, 2023 | 22 | $609.79M | vs. Q1 2023 | SEC |
| Q1 2023 | May 15, 2023 | 22 | $513.03M | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 14, 2023 | 21 | $566.61M | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 14, 2022 | 21 | $333.4M | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 15, 2022 | 22 | $235.41M | vs. Q1 2022 | SEC |
| Q1 2022 | May 16, 2022 | 20 | $249.1M | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 18, 2022 | 15 | $213.56M | – | SEC |